- Report
- January 2024
- 200 Pages
Global
From €4856EUR$5,000USD£4,189GBP
- Report
- March 2024
- 200 Pages
Global
From €4031EUR$4,150USD£3,477GBP
- Report
- April 2023
- 112 Pages
Global
From €4614EUR$4,750USD£3,980GBP
- Report
- February 2022
- 220 Pages
Global
From €9227EUR$9,500USD£7,960GBP
- Drug Pipelines
- June 2022
- 101 Pages
Global
From €10679EUR$10,995USD£9,212GBP
- Drug Pipelines
- January 2022
- 30 Pages
Global
From €486EUR$500USD£419GBP
- Report
- January 2019
- 35 Pages
Global
From €971EUR$1,000USD£838GBP
Entresto (sacubitril/valsartan) is a cardiovascular drug used to treat heart failure. It is a combination of two drugs, sacubitril and valsartan, which work together to reduce the strain on the heart. Entresto is a neprilysin inhibitor, which helps to reduce the amount of sodium and water in the body, and valsartan, an angiotensin receptor blocker, which helps to relax the blood vessels. Entresto is used to reduce the risk of cardiovascular death and hospitalization for heart failure in adults.
Entresto is a relatively new drug, having been approved by the FDA in 2015. It is currently the only neprilysin inhibitor approved for the treatment of heart failure. Entresto is available in both tablet and oral suspension form.
The Entresto market is highly competitive, with several major pharmaceutical companies competing for market share. These include Novartis, Merck, Pfizer, and AstraZeneca. Other companies, such as Amgen, Bristol-Myers Squibb, and GlaxoSmithKline, also have a presence in the market. Show Less Read more
